Clinical Trials Sponsored by Regenerex, LLC

Total 11390 results

Regeneron Pharmaceuticals

Recruiting

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy (Honey-B)

Hemophilia B

United States, Germany, United Kingdom, Canada
Regeneron Pharmaceuticals

Recruiting

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Advanced Solid Tumor | Metastatic Solid Tumor

Netherlands
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Regeneron Pharmaceuticals

Recruiting

Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen

Chronic Kidney Disease (CKD)

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)

Generalized Myasthenia Gravis

Korea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
Regeneron Pharmaceuticals

Recruiting

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Squamous Cell Carcinoma of Head and Neck

United States, Spain
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Hypertriglyceridemia

United States, Germany, Netherlands, Canada
Regeneron Pharmaceuticals

Completed

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) (LEAP)

Familial Partial Lipodystrophy | Metabolic Abnormalities

United States, France, Spain, Turkey, United Kingdom
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss (COURAGE)

Obesity

United States
Regeneron Pharmaceuticals

Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Conjunctivitis | Allergic Rhinitis

Canada
Regeneron Pharmaceuticals

Available

Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab

Paroxysmal Nocturnal Hemoglobinuria (PNH) | CD55-deficient Protein-losing Enteropathy (PLE) | CD59 Deficiency
Regeneron Pharmaceuticals

Available

Compassionate Use of Vidutolimod
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

Paroxysmal Nocturnal Hemoglobinuria

United States
Regeneron Pharmaceuticals

Completed

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy

Belgium
Regeneron Pharmaceuticals

Available

A Compassionate Use (CU) Program of Odronextamab

Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | B-Cell Non-Hodgkin Lymphoma (NHL) | High-Grade B-Cell Lymphoma (HGBCL)
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Allergic Rhinitis Due to Cat Allergy

United States, Belgium, Germany, Poland, Canada, France
Regeneron Pharmaceuticals

Completed

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Terminated

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

COVID-19

United States
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

Healthy

Belgium
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Hypercholesterolemia

United States, Spain, Australia, Netherlands, Japan, Jordan, Denmark, Israel, Sweden, South Africa, Canada, Austria, Czechia, France, Italy, New Zealand, Norway, Poland, Russian Federation, United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Conjunctivitis | Allergic Rhinitis

United States, Belgium, Canada, Denmark, Germany
Regeneron Pharmaceuticals

Completed

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

Malignant Melanoma

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

COVID-19

United States
Regeneron Pharmaceuticals

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Completed

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Chorioretinal Vascular Disease

United States
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Terminated

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (UPSURGE)

Gout

United States
Regeneron Pharmaceuticals

Completed

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 (PRE-SURGE1)

Intercritical Gout

United States, Canada
Regeneron Pharmaceuticals

Completed

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

Gout

Germany, Taiwan, India, South Africa, Indonesia
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals

Completed

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Neovascular Wet Age-related Macular Degeneration (AMD)

United States
Regeneron Pharmaceuticals

Completed

Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers

Healthy Volunteers

Australia
Regeneron Pharmaceuticals

Terminated

Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

Back Pain

United States
Regeneron Pharmaceuticals

Completed

A Study of Tocilizumab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Greater Houston Retina Research
Regeneron Pharmaceuticals; Clinical Trials Resource Group, LLC

Active, not recruiting

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (VOYAGE)

Diabetic Retinopathy

United States, Puerto Rico

3

Subscribe